



1641
JLW

TRANSMITTAL FORM

Application Serial Number	10/019,740
Filing Date	December 28, 2001
First Named Inventor	Cauwenberghs
Group Art Unit	1641
Examiner Name	Jung, Unsu
Attorney Docket No.	INL-091
Patent No.	Not applicable
Issue Date	Not applicable


ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Check Attached <input type="checkbox"/> Copy of Fee Transmittal Form <input type="checkbox"/> Amendment/Response to Restriction Requirement <input type="checkbox"/> Preliminary <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets ____] <input type="checkbox"/> Petition for Extension of Time <input checked="" type="checkbox"/> Information Disclosure Statement <input checked="" type="checkbox"/> Form PTO-1449 <input checked="" type="checkbox"/> Copies of IDS Citations B1-B2 and C1-C50 <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Sequence Listing submission <input type="checkbox"/> Paper Copy/CD <input type="checkbox"/> Computer Readable Copy <input type="checkbox"/> Statement verifying identity of above	<input type="checkbox"/> Copy of Notice to File Missing Parts of Application <input type="checkbox"/> Formal Drawing(s) <input type="checkbox"/> Request For Continued Examination (RCE) Transmittal <input type="checkbox"/> Power of Attorney (Revocation of Prior Powers) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> CD(s) for large table or computer program <input type="checkbox"/> Amendment After Allowance <input type="checkbox"/> Request for Certificate of Correction <input type="checkbox"/> Certificate of Correction (in duplicate)	<input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences <input type="checkbox"/> Appeal Brief (in triplicate) <input type="checkbox"/> Status Inquiry <input checked="" type="checkbox"/> Return Receipt Postcard <input checked="" type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8 <input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8 <input type="checkbox"/> Additional Enclosure(s) (please identify below)
--	---	---

CORRESPONDENCE ADDRESS

Direct all correspondence to: Patent Administrator
Kirkpatrick & Lockhart Nicholson
Graham LLP
75 State Street
Boston, MA 02109-1808
Tel. No.: (617) 261-3100
Fax No.: (617) 261-3175

SIGNATURE BLOCK

Respectfully submitted,

Fangli Chen, Ph.D.
Atty/Agent for Applicant(s)
Kirkpatrick & Lockhart Nicholson
Graham LLP
75 State Street
Boston, MA 02109-1808

Date: October 21, 2005
Reg. No. 51,551
Tel. No.: (617) 261-3198
Fax No.: (617) 261-3175



PATENT
Attorney Docket No. INL-091

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Cauwenberghs *et al.*
SERIAL NO.: 10/019,740 GROUP NO.: 1641
FILING DATE: December 28, 2001 EXAMINER: Jung, Unsu
TITLE: DETECTION OF VON-WILLEBRAND FACTOR (vWF) ACTIVITY

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the non-U.S. patent documents and non-patent publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- ☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☐ (2) after the period defined in (1) above but before the mailing date of any of a **final action** under 37 C.F.R. 1.113, a **notice of allowance** under 37 C.F.R. 1.311, or an action that otherwise closes prosecution in the application, and
- ☐ the requisite Statement is below, **OR**
- ☐ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein; or
- ☐ (3) after the period defined in (2) above but before the payment of the **issue fee**, **AND**

- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.


It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

Applicants submit that no fee is required for submission of this paper. However, in the event that any fee is required, please consider this a conditional authorization to change any required fee to Deposit Account No. 50-1721.


Date: October 21, 2005
Reg. No. 51,551

Tel. No.: (617) 261-3198
Fax No.: (617) 261-3175

Respectfully submitted,



Fangli Chen, Ph.D.
Atty/Agent for Applicant(s)
Kirkpatrick & Lockhart Nicholson
Graham LLP
75 State Street
Boston, Massachusetts 02109-1808



PATENT
Attorney Docket No. INL-091

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Cauwenberghs *et al.* CONF NO.: 7478
SERIAL NO.: 10/019,740 GROUP NO.: 1641
FILING DATE: December 28, 2001 EXAMINER: Jung, Unsu
TITLE: DETECTION OF VON-WILLEBRAND FACTOR (vWF) ACTIVITY

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, is/are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 21st day of October, 2005.



Kelly Ciarmataro

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith is/are:


1. Transmittal Form (1 pg.);
2. Information Disclosure Statement (2 pgs.);
3. Form PTO-1449 (5 pgs.);
4. Copies of IDS Citations (B1-B2 and C1-C50); and
5. Return receipt postcard.




FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: INL-091 APPLICANT(S): Cauwenberghs <i>et al.</i> SERIAL NO.: 10/019,740 FILING DATE: December 28, 2001 GROUP NO.: 1641				
U.S. PATENT DOCUMENTS								
EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
	A1	5,231,033	07/27/1993	Fickenscher			05/23/1991	
FOREIGN PATENT DOCUMENTS								
EXAM. INIT.	DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B1	92/16225	10/01/1992	WO			N	Y
	B2	01/02853	01/11/2001	WO			N	Y
OTHER ART, JOURNAL ARTICLES, ETC.								
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)							
	C1	Aihara <i>et al.</i> , (1988), "Plasma Collagen Cofactor Correlates with von Willebrand Factor Antigen and Ristocetin Cofactor but Not with Bleeding Time," <u>Thromb. Haemost.</u> , 59(3):485-490.						
	C2	Berliner <i>et al.</i> , (1988), "Generation and Characterization of Peptide-specific Antibodies That Inhibit Von Willebrand Factor Binding to Glycoprotein IIb-IIIa without Interacting with Other Adhesive Molecules, <u>J. Bio. Chem.</u> , 263:7500-7505.						
	C3	Brown <i>et al.</i> , (1986), "An ELISA Test for the Binding of von Willebrand Antigen to Collagen," <u>Thromb. Res.</u> , 43:303-311.						
	C4	Casonato <i>et al.</i> , (1998), "The Evaluation of Factor VIII Binding Activity of von Willebrand Factor by Means of an ELISA Method, <i>Significance and Practical Implications</i> ," <u>Am. J. Clin. Path.</u> , 109:347-352.						
	C5	De Marco <i>et al.</i> , (1986), "von Willebrand Factor Interaction with the Glycoprotein IIb/IIIa Complex, Its role in Platelet Function as Demonstrated in Patients with Congenital Afibrinogenemia," <u>J. Clin. Invest.</u> , 77:1272-1277.						
EXAM. INER				DATE CONSIDERED				



INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: INL-091 APPLICANT(S): Cauwenberghs <i>et al.</i> SERIAL NO.: 10/019,740 FILING DATE: December 28, 2001 GROUP NO.: 1641	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C6	Depraetere <i>et al.</i> , (1988), "Platelet Aggregation Induced by a Monoclonal Antibody to the A1 Domain of von Willebrand Factor," <u>Blood</u> , 91:3792-3799.	
	C7	Ewenstein, (1997), "Von Willebrand's Disease," <u>Annu. Rev. Med.</u> , 48:525-542.	
	C8	Falkenberg <i>et al.</i> , (1995), "In vitro production of monoclonal antibodies in high concentration in a new and easy to handle modular minifermenter," <u>Immunol. Methods</u> , 179:13-29.	
	C9	Favaloro <i>et al.</i> , (1991), "Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between Type I and Type II, von Willebrand's disease," <u>Blood Coagul. Fibrinolysis</u> , 2:285-291.	
	C10	Favaloro <i>et al.</i> , (1993), "von Willebrand's Disease: Laboratory Investigation Using an Improved Functional Assay for von Willebrand Factor," <u>Pathology</u> , 25:152-158.	
	C11	Favaloro <i>et al.</i> , (1995), "Laboratory Assessment of von Willebrand Factor, <i>Use of Different Assays Can Influence the Diagnosis of von Willebrand's Disease, Dependent on Differing Sensitivity to Sample Preparation and Differential Recognition of High Molecular Weight VWF Forms</i> ," <u>Am. J. Clin. Pathol.</u> , 104:(3)264-271.	
	C12	Favaloro <i>et al.</i> , (1997), "Laboratory Assays For von Willebrand Factor: Relative Contribution to the Diagnosis of von Willebrand's Disease," <u>Pathology</u> , 29:385-91.	
	C13	Federici <i>et al.</i> , (1989), "Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size," <u>Br. J. Haemato.</u> , 73:93-99.	
	C14	Federici <i>et al.</i> , (2004), "A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Iba for the diagnosis of patients with low von Willebrand factor levels," <u>Haematologica</u> , 89:77-85.	
	C15	Fischer <i>et al.</i> , (1996), "Effect of Multimerization of Human and Recombinant von Willebrand Factor on Platelet Aggregation, Binding to Collagen and Binding of Coagulation Factor VIII," <u>Thromb. Res.</u> , 84(1):55-66.	
	C16	Fischer <i>et al.</i> , (1998), "von Willebrand Factor: Measuring its Antigen or Function? Correlation between the Level of Antigen, Activity, and Multimer Size using Various Detection systems," <u>Thromb. Res.</u> , 91:39-43.	
	C17	Furlan <i>et al.</i> , (1985), "Reactivity of Small Molecular Forms of Human Factor VII/von Willebrand Factor with Botrocetin and Anti-Factor VIII-Coated Latex Particles," <u>Thromb. Haemost.</u> , 54(2):463-465.	
	C18	Galfre <i>et al.</i> , (1981), "Preparation of Monoclonal Antibodies: Strategies and Procedures," <u>Meth. Enzymol.</u> , 73:3-46.	
	C19	Harsfalvi <i>et al.</i> , (1995), "Calin From Hirudo Medicinalis, an Inhibitor of von Willebrand Factor Binding to Collagen Under Static and Flow Conditions," <u>Blood</u> , 85(3):705-711.	
EXAM.INER		DATE CONSIDERED	



FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: INL-091 APPLICANT(S): Cauwenberghs <i>et al.</i> SERIAL NO.: 10/019,740 FILING DATE: December 28, 2001 GROUP NO.: 1641
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C20	Howard <i>et al.</i> , (1971), "Ristocetin-A New Tool in the Investigation of Platelet Aggregation," <u>Thromb. Diath. Haemorrh.</u> , 26:362-369.
	C21	Hoylaerts <i>et al.</i> , (1995), "Promotion of binding of von Willebrand factor to platelet glycoprotein Ib by dimers of ristocetin," <u>Biochem. J.</u> , 306:453-463
	C22	Hoylaerts <i>et al.</i> , (1997), "von Willebrand factor binds to native collagen VI primarily via its A1 domain," <u>Biochem. J.</u> , 324:185-191.
	C23	Ingerslev, (1987), "A sensitive ELISA for von Willebrand factor (vWf:Ag); <u>Scand. J. Clin. Lab. Invest.</u> , 47:143-149.
	C24	Köhler <i>et al.</i> , (1975), "Continuous cultures of fused cells secreting antibody of predefined specificity," <u>Nature</u> , 256:495-497.
	C25	Lankhof <i>et al.</i> , (1996), "A3 Domain Is Essential for Interaction of von Willebrand Factor with Collagen Type III," <u>Thromb. Haemost.</u> , 75:950-958.
	C26	Li <i>et al.</i> , (2001), "Expression of the Amino-Terminal Domain of Platelet Glycoprotein Ib α : Exploitation of a Calmodulin Tag for Determination of Its Functional Cavity," <u>Protein Expression and Purification</u> , 22:200-210.
	C27	Macfarlane <i>et al.</i> , (1975), "A Method for Assaying von Willebrand Factor (Ristocetin Cofactor)," <u>Thromb. Diath. Haemorrh.</u> , 34:306-308.
	C28	Marchese <i>et al.</i> , (1999), "Adhesive properties of the isolated Amino-terminal domain of platelet glycoprotein Ib α in a flow field," <u>Proc. Natl. Acad. Sci. USA</u> , 96:7837-7842.
	C29	Merrifield, (1963), "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide," <u>J. Am. Chem. Soc.</u> , 85:2149-2155.
	C30	Meyer <i>et al.</i> , (1993), "Expression and Characterization of Functionally Active Fragments of the Platelet Glycoprotein (GP) Ib-IX Complex in Mammalian Cells," <u>J. Bio. Chem.</u> , 268(27):20555-20562.
	C31	Mohlke <i>et al.</i> , (1997), "von Willebrand disease and quantitative variation in von Willebrand factor," <u>J. Lab. Clin. Med.</u> , 130:252-261.
	C32	Murata <i>et al.</i> , (1991), "Site-directed Mutagenesis of a Soluble Recombinant Fragment of Platelet Glycoprotein Ib α Demonstrating Negatively Charged Residues Involved in von Willebrand Factor Binding," <u>J. Biol. Chem.</u> , 266(23):15474-15480.
	C33	Murata <i>et al.</i> , (1993), "Expression of the Phenotypic Abnormality of Platelet-Type von Willebrand Disease in a Recombinant Glycoprotein Ib α Fragment," <u>J. Clin. Invest.</u> , 91:2133-2137.
	C34	Murdock <i>et al.</i> , (1997), "von Willebrand Factor Activity Detected in a Monoclonal Antibody-based ELISA: an Alternative to the Ristocetin Cofactor Platelet Agglutination Assay for Diagnostic Use," <u>Thromb. Haemost.</u> , 78:1272-1277.
EXAM. INER		DATE CONSIDERED



INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: INL-091 APPLICANT(S): Cauwenberghs <i>et al.</i> SERIAL NO.: 10/019,740 FILING DATE: December 28, 2001 GROUP NO.: 1641
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C35	Ng <i>et al.</i> , (1999), "Imaging Protein Kinase C α Activation in Cells," <u>Science</u> , 283:2085-2089.
	C36	Obert <i>et al.</i> , (1999), "Conformational Changes in the A3 Domain of von Willebrand Factor Modulate the Interaction of the A1 Domain With Platelet Glycoprotein Ib," <u>Blood</u> , 93:1959-1968.
	C37	Petersen <i>et al.</i> , (1996), "Functional Expression of Single Chain Glycoprotein Ib Alpha on the Surface of COS Cells and BHK Cells," <u>Thromb. Haemost.</u> , 76(5):768-773.
	C38	Petersen <i>et al.</i> , (1992), "Transient Expression of Recombinant Glycoprotein Ib α Polypeptides in COS Cells that Inhibit von Willebrand Factor Binding to the Platelet Glycoprotein Ib/IX Complex," <u>Thromb. Haemost.</u> , 68(2):203-207.
	C39	Preston, (1998), "Assays for von Willebrand Factor Functional Activity: A UK NEQAS Survey," <u>Thromb. Haemost.</u> , 80:863.
	C40	Rodeghiero <i>et al.</i> , (1987), "Epidemiological Investigation of the Prevalence of von Willebrand's Disease," <u>Blood</u> , 69:454-9.
	C41	Ruggeri <i>et al.</i> , (1983), "Platelets Have More Than One Binding Site for von Willebrand Factor," <u>J. Clin. Invest.</u> , 72:1-12.
	C42	Sadler, (1994), "A Revised Classification of von Willebrand Disease, For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis," <u>Thromb. Haemost.</u> , 71:520-5.
	C43	Sakariassen <i>et al.</i> , (1983), "A perfusion chamber developed to Investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components," <u>J. Lab. Clin. Med.</u> , 102:522-535.
	C44	Sixma <i>et al.</i> , (1991), "Effect of deletion of the A1 domain of von Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin," <u>Eur. J. Bio. Chem.</u> , 196:369-375.
	C45	Thomas <i>et al.</i> , (1994), "Ein einfacher Test für die Bestimmung der Funktion des Von-Willebrand-Faktors: die Kollagenbindungsaktivität," <u>Hämostaseologie</u> , 14:133-9. (English abstract provided).
	C46	Tornai <i>et al.</i> , (1993), "A Monoclonal Antibody Recognizes a von Willebrand Factor Domain within the Amino-terminal Portion of the Subunit that Modulates the Function of the Glycoprotein IB- and IIB/IIIA-binding Domains," <u>J. Clin. Invest.</u> , 91:273-282.
	C47	Vanhoorelbeke <i>et al.</i> , (2000), "A Reliable and Reproducible ELISA Method to Measure Ristocetin Cofactor Activity of von Willebrand Factor," <u>Thromb. Haemost.</u> , 83:107-113.
	C48	Veyradier <i>et al.</i> , (1998), "Laboratory diagnosis of von Willebrand disease," <u>Int. J. Clin. Lab. Res.</u> , 28:201-210.
EXAM.INER		DATE CONSIDERED



FORM PTO - 1449		ATTORNEY DOCKET NO.: INL-091	
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Cauwenberghs <i>et al.</i>	
		SERIAL NO.: 10/019,740	
		FILING DATE: December 28, 2001	
		GROUP NO.: 1641	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C49	Vicente <i>et al.</i> , (1988), "Isolation and Functional Characterization of the von Willebrand Factor-binding Domain Located between Residues His ¹ -Arg ²⁹³ of the α -Chain of Glycoprotein Ib," <u>J. Bio Chem.</u> , 263:18473-18479.	
	C50	Wittmann-Liebold <i>et al.</i> , (1994), "Analysis and Characterization of Proteins," <u>Concepts in Protein Engineering and Design An Introduction</u> (Wrede Eds.), Walter de Gruyter, Berlin, New York, pp. 1-106.	
EXAM.INER		DATE CONSIDERED	